A detailed history of Marotta Asset Management transactions in Genmab A/S stock. As of the latest transaction made, Marotta Asset Management holds 13,532 shares of GMAB stock, worth $278,623. This represents 0.06% of its overall portfolio holdings.

Number of Shares
13,532
Previous 13,643 0.81%
Holding current value
$278,623
Previous $342,000 3.8%
% of portfolio
0.06%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$23.84 - $28.48 $2,646 - $3,161
-111 Reduced 0.81%
13,532 $329,000
Q2 2024

Jul 17, 2024

SELL
$25.13 - $30.27 $35,156 - $42,347
-1,399 Reduced 9.3%
13,643 $342,000
Q1 2024

Apr 02, 2024

SELL
$26.43 - $32.77 $13,822 - $17,138
-523 Reduced 3.36%
15,042 $449,000
Q4 2023

Jan 03, 2024

SELL
$27.94 - $35.44 $24,754 - $31,399
-886 Reduced 5.39%
15,565 $495,000
Q3 2023

Oct 11, 2023

SELL
$35.27 - $42.24 $19,857 - $23,781
-563 Reduced 3.31%
16,451 $580,000
Q2 2023

Jul 05, 2023

SELL
$37.4 - $42.94 $7,667 - $8,802
-205 Reduced 1.19%
17,014 $646,000
Q4 2022

Jan 03, 2023

SELL
$33.8 - $47.06 $1,656 - $2,305
-49 Reduced 0.28%
17,219 $0
Q3 2022

Oct 11, 2022

BUY
$31.52 - $373.61 $2,300 - $27,273
73 Added 0.42%
17,268 $554,000
Q2 2022

Jul 21, 2022

SELL
$26.83 - $38.57 $1,663 - $2,391
-62 Reduced 0.36%
17,195 $558,000
Q1 2022

Apr 08, 2022

SELL
$30.95 - $39.68 $4,890 - $6,269
-158 Reduced 0.91%
17,257 $624,000
Q4 2021

Jan 13, 2022

BUY
$35.87 - $47.12 $12,877 - $16,916
359 Added 2.1%
17,415 $688,000
Q3 2021

Oct 21, 2021

SELL
$41.55 - $48.72 $8,642 - $10,133
-208 Reduced 1.2%
17,056 $745,000
Q2 2021

Jul 09, 2021

BUY
$32.88 - $44.57 $63,261 - $85,752
1,924 Added 12.54%
17,264 $704,000
Q1 2021

Apr 09, 2021

BUY
$30.92 - $44.4 $474,312 - $681,096
15,340 New
15,340 $503,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Marotta Asset Management Portfolio

Follow Marotta Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marotta Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Marotta Asset Management with notifications on news.